| DON'T BUY | 4.500 | Benj Gallander | When a biotech finds the right thing, the stock can jump like crazy. This company just had a 1 for 10 reverse split. 90% of companies that do a reverse split are still down one year later. | 2007-04-19 | |
| DON'T BUY | 0.430 | Larry Berman CFA, CMT, CTA | This one is past the point of no return. Speculative. | 2007-02-21 | |
| PAST TOP SHORT | 6.160 | Andrew McCreath | (A Top Short Sept 8/04. Sold in low $5's so he's ahead about 19%.) | 2005-01-17 | |
| BUY | 6.450 | Robert Floyd | Have been building up their balance sheet to complete their final trials. Are now approaching a critical time. Feels the company can start to look better from here. | 2005-01-07 | |
| TOP SHORT | 6.500 | Andrew McCreath | Doesn't feel they have a lot of R&D to show. Have a lot of cash on the books. | 2004-09-08 | |
| BUY | 7.600 | Ed Ho | Interesting technology. | 2004-03-24 | |
| HOLD | 8.980 | Peter Hodson | Have signed on with a bigger company and now have to wait for the revenues and earnings to kick in. Easy money has been made. | 2004-01-23 | |
| DON'T BUY | 7.470 | David Burrows | They are risk model on bile tax turned negative a couple of months ago so they sold their holdings. Well-run and has an interesting product. They are in the process of being listed in the US. Wait for some strength in that sector. | 2003-12-16 | |
| DON'T BUY | 6.750 | Brian Acker, CA | Have no earnings and won’t for the next 3 years. Model price is $1.50. | 2003-11-20 | |
| DON'T BUY | 7.980 | Jonathen Wellum, B. Comm, B. Sc | Prefers companies with consistent earnings. Too speculative for them. | 2003-09-26 | |
| WEAK BUY | 5.800 | Peter Hodson | Looks like some one is accumulating it. Well run. A little expensive now. | 2003-05-12 | |
| STRONG BUY | 4.800 | Robert Floyd | Bullish on the stock. 2 trials are in phase 3. Good cash position. | 2003-04-10 | |
| WEAK BUY | 3.950 | David Burrows | Interesting technology. Sector is doing well. Speculative. | 2003-04-01 | |
| BUY | 4.230 | Robert Floyd | Looking at a number of phase 3 trials. Good management. | 2003-03-03 | |
| HOLD | 2.800 | Robert Floyd | They have done what they said they would. | 2002-10-10 | |
| WEAK BUY | 4.200 | Robert Floyd | Interesting product line. New issue has diluted the price. Will take a long time. | 2002-06-26 | |
| DON'T BUY | 4.950 | Bruce Cooper | Quite risky. No earnings. | 2002-05-17 | |
| WEAK BUY | 5.200 | John Sinkins, CFA | Good company and good science. Moving into phase 2 and could take a while.Good pipeline. | 2002-05-09 | |
| TOP PICK | 5.480 | Robert Floyd | Strong balance sheet and good management. Has a product in phase 3. Good price. | 2002-04-25 | |
| TOP PICK | 6.600 | Robert Floyd | Good cash position. Partnership with Quest. Strong management. | 2002-03-14 | |
| BUY | 5.920 | Robert Floyd | Strong balance sheet. Good products going through the FDA trials, one in phase 3. At a good price. | 2002-02-08 | |
| PAST TOP PICK | 6.500 | Robert Floyd | (Was a top pick on Nov 22 down 17%) A news driven stock re: clinical trials. At a good price. | 2002-02-01 | |
| BUY | 7.300 | Joe Connolly | At a good price. | 2002-01-03 | |
| BUY | 7.200 | Robert Floyd | Strong cash position. Nice joint venture. Strong management. | 2001-12-21 | |
| TOP PICK | 7.950 | Robert Floyd | New joint venture with US company is good. At a good price. | 2001-11-22 | |
| TOP PICK | 7.700 | Robert Floyd | In a joint venture with Quest which is good. Good risk/reward. | 2001-11-09 | |
| BUY | 11.000 | Rob Callander | Looks good. Put a stop loss at $9. | 2001-05-24 | |
| DON'T BUY | 11.000 | David Driscoll | Good products in final phase, but a one trick pony. | 2001-05-24 | |
| PAST TOP PICK | 9.120 | Robert Floyd | (Was a top pick on Aug 29/00 down 15%) Has been up. At an excellent price. Buy. | 2001-05-14 | |
| TOP PICK | 9.500 | Robert Floyd | A number of products in different phases. Lots of cash. | 2001-04-30 | |
| BUY | 8.350 | Robert Floyd | Getting into phase 2. Likes their growth strategy. | 2001-03-15 | |
| TOP PICK | 8.850 | Robert Floyd | Large markets. Good contacts/management. Strong balance sheet. Wide variety of products | 2001-01-03 | |
| WATCH | 8.900 | Steven Misener | Could be an interesting stock | 2001-01-02 | |
| STRONG BUY | 10.000 | Robert Floyd | Likes. Big market sector A lot of cash | 2000-11-01 | |
Experts that have talked about Vasogin
Rss Top Picks Feed
